A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Cancer Biology Bookmark and Share

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • To say that myelofibrosis patients need more treatment options would be an understatement. The severely low platelet counts, known as thrombocytopenia, that are one of the hallmark symptoms of the disease can lead to chronic fatigue and weakness that not only damage quality of life but, ultimately, shorten life...
  • Patients with metastatic colorectal cancer often stop responding to the primary drugs used against the disease, leaving them with few options and little hope. Determined to increase those options, doctors and researchers at City of Hope are conducting two clinical trials that could lead to new treatments for pe...
  • Investigators working at City of Hope are making many significant inroads against many forms of cancer. To do that, they have to take a variety of approaches. Molecular oncology researchers focus on abnormal cancer-associated activity in a cell’s nucleus. One especially prominent factor in many breast and ovari...
  • In light of the new breast cancer screening guidelines, which call for women to have mammograms every other year from age 50 to 74, it’s more important than ever for women to understand their individual risk. On Monday, the U.S. Preventive Services Task force released new breast cancer screening guideline...
  • Cancer patients need, and deserve, more than medical care. They and their families need high-quality supportive care – that is, care that addresses their physical, emotional and spiritual well-being. Health care professionals increasingly understand this, but starting such programs from scratch isn’t easy...
  • Each year, City of Hope patients given another chance at life gather to pose for a picture like this one. Going on its 39th year, the celebration of patients free of blood cancers thanks to bone marrow or stem cell transplants has grown such that a photographer has to scale a cherry picker just to […]
  • Cancer patients who are participating in early-stage clinical trials need extra emotional and physical support due to their additional stress and often unique symptoms. Now an effort by researchers at City of Hope to create a model for such support has received a $6.8 million grant from the National Cancer Inst...
  • The need for improvements in treating malignant brain tumors has never been greater. Survival for many patients with these tumors are sometimes measured in just months. One reason that therapeutic options are limited is that traditional surgery is deemed too risky for many brain tumors, especially for those in ...
  • “Honestly, there’s nothing special about my story,” protested Daniel Samson, as he bounced Layla, his 3 1/2-year-old daughter, on his lap and put on a video for her to watch. “I just want to tell it for my own sake, and share it with other men who may be going through this chaos.” Samson spoke […]
  • As far back as he can remember, Jonathan Yamzon, M.D., wanted to be a doctor. “I knew it from the get-go,” he said, matter-of-factly. “I always envisioned it as the ideal; the supreme thing one could do with one’s life.” The youngest of six children, Yamzon was barely a toddler when his family moved to [&...
  • There’s never a “good” time for cancer to strike. With testicular cancer, the timing can seem particularly unfair. This disease targets young adults in the prime of life; otherwise healthy people unaccustomed to any serious illness, let alone cancer. And suddenly … “I can only imagine what they must...
  • Sure, a healthy lifestyle can lower a person’s risk, but the impact of specific actions is harder to tease out. Diet, exercise, tobacco use, nutritional supplements, alcohol consumption … How important are each of these factors, individually? Does strict adherence to (or rejection of) one get you a pass o...
  • Health care decisions are tough. They’re even tougher when you – or loved ones – have to make them without a plan or a conversation. National Healthcare Decisions Day, on April 16,  is a nationwide initiative to demystify the health care decision-making process and encourage families to start talking. Ult...
  • The statistics, direct from the American Cancer Society, are sobering: Cancer death rates among African-American men are 27 percent higher than for white men. The death rate for African-American women is 11 percent higher compared to white women. Hispanics have higher rates of cervical, liver and stomach cancer...
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...